2003
DOI: 10.1046/j.1365-2141.2003.03849.x
|View full text |Cite|
|
Sign up to set email alerts
|

The role of hydroxyurea in sickle cell disease

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

2
98
0
13

Year Published

2004
2004
2019
2019

Publication Types

Select...
4
4

Relationship

0
8

Authors

Journals

citations
Cited by 126 publications
(113 citation statements)
references
References 73 publications
2
98
0
13
Order By: Relevance
“…Although there is controversy over the leukemogenicity of hydroxyurea in MPDs, extensive experience with the drug in sickle cell anemia suggests that hydroxyurea does not commonly induce leukemic transformation of normal stem cells. 38 It is therefore difficult to explain why patients PV2 and ET1 would develop leukemia in a normal stem cell following therapy with hydroxyurea alone.…”
Section: Discussionmentioning
confidence: 99%
“…Although there is controversy over the leukemogenicity of hydroxyurea in MPDs, extensive experience with the drug in sickle cell anemia suggests that hydroxyurea does not commonly induce leukemic transformation of normal stem cells. 38 It is therefore difficult to explain why patients PV2 and ET1 would develop leukemia in a normal stem cell following therapy with hydroxyurea alone.…”
Section: Discussionmentioning
confidence: 99%
“…Hydroxyurea (HU) is an important and effective therapy for patients with sickle cell disease [1,2]. A number of different mechanisms have been proposed to explain the clinical benefits seen in patients with SCD treated with HU.…”
Section: Introductionmentioning
confidence: 99%
“…10]. Although the potential leukemogenic/carcinogenic effect of HU [2] has been raised as a major contributor to this phenomenon, there remains a lack of literature addressing the prescribing patterns of HU by physicians outside the context of medical centers with interest in the management of SCD. We therefore performed a mail survey to address the practices and patterns of HU use by community hematologists/ oncologists (H/Os).…”
Section: Introductionmentioning
confidence: 99%
“…4 In addition to its myelosuppressive effect and ability to induce fetal hemoglobin (HbF) synthesis, HU has been shown to reduce the adhesion of sickle erythrocytes to endothelial cells and to modulate endothelial cell activation and nitric oxide generation. 5 Whereas HU clinical benefits in severely affected adult SCD patients were confirmed by a randomized controlled trial in 1995 (MSH), 1,6 its role in very young children requires further studies. 2,[7][8][9][10] Unanswered questions remain about its sustained efficacy and long-term safety, especially in children who might be exposed to HU for decades.…”
Section: Introductionmentioning
confidence: 99%